B/BE/04/BV1
| Company/Institution | Pfizer, Animal Health Group |
| Parental organism | Feline Herpes Virus |
| Transgene(s) | gene for the env glycoprotein or gene for the gag protein of the Feline immunodeficiency virus (FIV) |
| Treated organism | cats |
| Title of the project | Evaluation of the safety of Feline Herpes Virus, bivalent deleted live vaccine, administered as intranasal vaccine to cats |
| Treatment indication | prevention and/or reduction of infection caused by Feline immunodeficiency virus (FIV) |
| Administration route(s) | intranasal |
| Total number of subjects foreseen | at least 40 animals, maximum 1000 animals |
| Foreseen duration of release | 1 year |
| Effective year(s) of release | - |
| Current status | Authorized but trial withdrawn by notifier |
| Locations | Mechelen, Sint Katelijne-Waver and Schaerbeek |
| Number of sites | 3: 1 veterinary clinic and 2 breeding catteries |
| Monitoring | see advice of the Biosafety Council (point 10 and Conclusion) |
| Type of procedure | Classical procedure - Art. 9§1 of Royal Decree of 18 December 1998 |
| Notes | |
| Other |
Information for the public
-
B/BE/04/BV1 - Summary Notification Information Format (SNIF)
Public information presented according to the provisions of Directive 2001/18/EC
- B/BE/04/BV1 - Public information sheet (written by the notifier)
- B/BE/04/BV1 - Fiche d'information destinée au public (préparée par le notifiant)
- B/BE/04/BV1 – Informatie fiche bestemd voor het publiek (voorbereid door de kennisgever)
Information related to the decision procedure
-
B/BE/04/BV1 - Advice Biosafety Advisory Council
15 July 2005: The Biosafety Advisory Council issues a positive advice (with conditions) for this trial.
-
B/BE/04/BV1 - Decision of the Federal Minister (FINAL DECISION)
1 September 2005: The Federal Minister gives a final decision (positive) for this trial, reminding the conditions requested by the Biosafety Advisory Council in its advice.
